Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | ARG1 | P05089 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL15865238 | 1.00 | SLC6A2 (0.53) | SLC6A2TAAR1SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL9271997 | 0.90 | TAAR1 (0.58) | SLC6A2TAAR1SMN1; SMN2HIF1ACYP1A2 | |
| Acetic Acid SCHEMBL27845326 | 0.83 | SMN1; SMN2 (0.50) | SLC6A2TAAR1SMN1; SMN2HIF1ACYP1A2 | |
| Acetic Acid SCHEMBL8540615 | 0.83 | SMN1; SMN2 (0.55) | SLC6A2TAAR1SMN1; SMN2HIF1ACYP1A2 | |
| Acetic Acid SCHEMBL6056055 | 0.83 | SMN1; SMN2 (0.55) | SLC6A2TAAR1SMN1; SMN2HIF1ACYP1A2 | |
| Acetic Acid SCHEMBL28784357 | 0.83 | SMN1; SMN2 (0.55) | SLC6A2TAAR1SMN1; SMN2HIF1ACYP1A2 | |
| Phentermine SCHEMBL8142147 | 0.82 | SLC6A2 (0.79) | SLC6A2TAAR1SMN1; SMN2HIF1ACYP1A2 | |
| Phentermine SCHEMBL5930925 | 0.79 | SLC6A2 (0.73) | SLC6A2TAAR1SMN1; SMN2HIF1ACYP1A2 | |
| Acetic Acid SCHEMBL28154484 | 0.79 | HIF1A (0.50) | SLC6A2TAAR1SMN1; SMN2HIF1ACYP1A2 | |
| Acetic Acid SCHEMBL28732415 | 0.78 | SLC6A2 (0.53) | SLC6A2TAAR1SMN1; SMN2HIF1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050129612-A1 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | ZACZEK ROBERT (US) | 2005-06-16 | — | — | US | claimed |
| US-6878363-B2 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-04-12 | — | — | US | claimed |
| US-20030152512-A1 | Imaging thrombus with glycoprotein llb/llla antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-08-14 | — | — | US | claimed |
| US-20020159947-A1 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | LANTHEUS MEDICAL IMAGING, INC. | 2002-10-31 | — | — | US | claimed |
| WO-2001087354-A2 | USE OF SMALL MOLECULE RADIOLIGANDS FOR DIAGNOSTIC IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-11-22 | — | — | WO | claimed |
| EP-0822835-A1 | HYBRID MAGNETIC RESONANCE CONTRAST AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 1998-02-11 | — | — | EP | claimed |
| US-5624661-A | Hypoosmotic compositions comprising a polymer and a complexed contrast agent for MRI | IMARX THERAPEUTICS, INC. | 1997-04-29 | — | — | US | claimed |
| WO-1996032967-A1 | HYBRID MAGNETIC RESONANCE CONTRAST AGENTS | IMARX PHARMACEUTICAL CORPORATION (US) | 1996-10-24 | — | — | WO | claimed |
| US-5407657-A | Containing a metal chelate and a free radical nitroxide | IMARX THERAPEUTICS, INC. | 1995-04-18 | — | — | US | claimed |
| EP-0442962-B1 | LIPOSOMAL RADIOLOGIC CONTRAST AGENTS | UNGER EVAN C (US) | 1994-01-05 | — | — | EP | claimed |
| US-20260091144-A1 | BIO-ACTIVATED REPORTERS TO VISUALIZE, IN REAL TIME, SPECIFIC GENE THERAPY PRODUCTS | UNIV NORTHWESTERN (US) | 2026-04-02 | — | — | US | disclosed |
| US-12508328-B2 | Bio-activated reporters to visualize, in real time, specific gene therapy products | NORTHWESTERN UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3611184-B1 | CELL PENETRATING PEPTIDE, CONJUGATE COMPRISING THE SAME, AND COMPOSITION COMPRISING CONJUGATE | GEMVAX & KAEL CO LTD (KR) | 2024-12-11 | — | — | EP | disclosed |
| US-12145875-B2 | Polyphosphate glass microspheres, methods of making and uses thereof | DALHOUSIE UNIVERSITY | 2024-11-19 | — | — | US | disclosed |
| EP-2873678-B1 | CONJUGATE COMPRISING A CELL-PENETRATING PEPTIDE AND COMPOSITIONS COMPRISING SAME | GEMVAX & KAEL CO LTD (KR) | 2024-06-26 | — | — | EP | disclosed |
| WO-1993006148-A1 | COPOLYMERS AND THEIR USE AS CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING AND IN OTHER APPLICATIONS | UNGER EVAN C (US) | 1993-04-01 | — | — | WO | disclosed |
| EP-0526503-A4 | POLYMERS AS CONTRAST MEDIA FOR MAGNETIC RESONANCE IMAGING | — | 1993-02-24 | — | — | EP | disclosed |
| EP-0526503-A1 | POLYMERS AS CONTRAST MEDIA FOR MAGNETIC RESONANCE IMAGING. | UNGER EVAN C (US) | 1993-02-10 | — | — | EP | disclosed |
| WO-1991015753-A1 | POLYMERS AS CONTRAST MEDIA FOR MAGNETIC RESONANCE IMAGING | UNGER EVAN C (US) | 1991-10-17 | — | — | WO | disclosed |
| WO-1990004943-A1 | LIPOSOMAL RADIOLOGIC CONTRAST AGENTS | UNGER EVAN C (US) | 1990-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508328-B2 | Bio-activated reporters to visualize, in real time, specific gene therapy products | GAA, GUSB, GBA3 | SLC6A2 1350/4885TAAR1 3112/4885SMN1; SMN2 235/4885 |
| US-20020159947-A1 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | APP, BACE1, BACE2 | SLC6A2 541/4885TAAR1 1297/4885SMN1; SMN2 3100/4885 |
| US-20050129612-A1 | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging | APP, BACE1, BACE2 | SLC6A2 572/4885TAAR1 987/4885SMN1; SMN2 3280/4885 |
| US-20030152512-A1 | Imaging thrombus with glycoprotein llb/llla antagonists | FGB, SELPLG, SELL | SLC6A2 1856/4885TAAR1 2227/4885SMN1; SMN2 4835/4885 |
| US-20260091144-A1 | BIO-ACTIVATED REPORTERS TO VISUALIZE, IN REAL TIME, SPECIFIC GENE THERAPY PRODUCTS | GAA, GUSB, GBA3 | SLC6A2 1040/4885TAAR1 2784/4885SMN1; SMN2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.